...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Expectations for the AGM?
Reply New Message
Prev Message Back To Forum Threaded View Next Message

I'd be opposed to a CVR deal.

Shadowy Shares: The Dark Side of Contingent Value Rights
Forbes, May 9, 2011.

"....CVRs can transfer much of the risk normally borne by acquirers to the shareholders in the target corporation...."

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply